11/18/2026 | Press release | Distributed by Public on 11/18/2026 15:14
As filed with the Securities and Exchange Commission on November 18, 2026
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OF 1933
OSR Health, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
84-5052822 |
|
(State or other jurisdiction of |
(I.R.S. Employer |
OSR Health, Inc. 2025 Omnibus Incentive Plan
(Full title of the plans)
Kuk Hyoun Hwang
Chief Executive Officer
10900 NE 4th Street, Suite 2300
Bellevue, WA 98004
(Name and address of agent for service)
Telephone: (425) 635-7700
(Telephone number, including area code, of agent for service)
With Copies to:
Jun Chul Whang
Chief Legal Officer
OSR Health, Inc.
10900 NE 4th Street, Suite 2300
Bellevue, WA 98004
Telephone: (425) 635-7700
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer |
☐ |
Accelerated filer |
☐ |
|
Non-accelerated filer |
☒ |
Smaller reporting company |
☒ |
|
Emerging growth company |
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
This Registration Statement on Form S-8 is being filed with the U.S. Securities and Exchange Commission (the "SEC") under the Securities Act of 1933, as amended (the "Securities Act"), to register 6,300,000 shares of common stock, par value $0.0001 per share ("Common Stock"), of OSR Health, Inc. (the "Company" or the "Registrant"), authorized for issuance under the OSR Health, Inc. 2025 Omnibus Incentive Plan (the "2025 Plan").
This Registration Statement also includes a reoffer prospectus, prepared pursuant to General Instruction C to Form S-8, in accordance with the requirements of Part I of Form S-3, to be used by the Company's directors and executive officers (which we refer to as the "Selling Stockholders"), as described under the section entitled "Selling Stockholders" therein, in connection with reoffers and resales on a continuous or delayed basis of up to 2,507,256 shares of Common Stock issuable under the 2025 Plan. The Selling Stockholders may be deemed to be "affiliates" of the Company within the meaning of Rule 405 under the Securities Act, and the shares of Common Stock covered by the reoffer prospectus may be deemed to constitute "control securities" within the meaning of General Instruction C to Form S-8.
The shares covered by the reoffer prospectus are subject to a six-month contractual transfer restriction period, and accordingly, offers and resales pursuant to the reoffer prospectus may not commence until expiration of such restriction period. The reoffer prospectus is intended to permit resales by the Selling Stockholders on a continuous or delayed basis following expiration of the applicable contractual restriction period pursuant to Rule 415 under the Securities Act. Prior to expiration of the applicable restriction period, the reoffer prospectus will not be used for offers or resales of the covered shares.
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
The documents constituting Part I of this registration statement will be delivered to plan participants as required by Rule 428(b)(1) under the Securities Act. These documents are not filed with the SEC as part of this registration statement but constitute a prospectus meeting the requirements of Section 10(a) of the Securities Act. This Registration Statement also includes a prospectus (the Reoffer Prospectus) prepared in accordance with General Instruction C of Form S-8 and in accordance with the requirements of Part I of Form S-3. This Reoffer Prospectus may be used for the reoffer and resale of shares of Common Stock on a continuous or delayed basis. The following legend shall conspicuously appear on each participant-facing plan information document: "This document constitutes part of a prospectus covering securities that have been registered under the Securities Act of 1933."
REOFFER PROSPECTUS
OSR HEALTH, INC.
(OTC: OSRH)
2,507,256 Shares of Common Stock
($0.0001 par value per share)
offered by the Selling Stockholders named herein pursuant to the
OSR Health, Inc. 2025 Omnibus Incentive Plan
This prospectus relates to up to 2,507,256 shares of common stock, par value $0.0001 per share (the "Common Stock"), of OSR Health, Inc. (the "Company"), which may be offered from time to time by certain stockholders that are our current directors and executive officers (the "Selling Stockholders") for their own accounts. We will not receive any of the proceeds from the sale of shares by the Selling Stockholders.
The shares may be acquired by the Selling Stockholders pursuant to awards granted under the Company's 2025 Omnibus Incentive Plan in connection with compensation arrangements with the Selling Stockholders. The awards were originally approved by the Board of Directors on April 28, 2026 (awards to executive officers and employees in settlement of unpaid salaries) and May 6, 2026 (awards to independent directors); on October 29, 2026, the Board and its Compensation Committee reset the grant date of the awards to October 29, 2026. Shares issuable to the Company's executive officers in settlement of unpaid salaries were granted on October 29, 2026, determined by reference to accrued compensation amounts, and will be issued at a price per share equal to 115% of the volume weighted average price of the Company's Common Stock for the 15 trading days ended October 28, 2026. Shares issuable to the Company's independent directors were granted on October 29, 2026, and consist of fully vested stock grants of 120,000 shares per director, granted in full settlement of previously approved equity compensation commitments to the independent directors.
The shares offered by this prospectus will be issued as registered securities under the registration statement of which this prospectus forms a part. The Selling Stockholders are directors and executive officers of the Company and may be deemed to be "affiliates" of the Company within the meaning of Rule 405 under the Securities Act. Because the Selling Stockholders may be deemed to be affiliates of the Company, the shares may be deemed to constitute "control securities" within the meaning of General Instruction C to Form S-8. To the extent the Selling Stockholders are deemed affiliates, resales of the shares by the Selling Stockholders may be subject to the volume, manner-of-sale and current public information requirements of Rule 144 under the Securities Act of 1933, as amended (the "Securities Act"), applicable to sales by affiliates, but are not subject to any Rule 144 holding period. This prospectus has been prepared to permit the resale of such shares by the Selling Stockholders from time to time in accordance with the Securities Act.
In addition, the shares issuable pursuant to the awards are subject to a contractual restriction on transfer and sale for a period of six months following the applicable grant date. Accordingly, the Selling Stockholders may not offer, sell or otherwise transfer the shares prior to the expiration of such restriction period, notwithstanding the effectiveness of the registration statement of which this prospectus forms a part.
The Selling Stockholders have advised the Company that they hold their shares as a long-term investment and, as of the date of this prospectus, have no present intention to sell any of the shares covered by this prospectus. The shares are subject to a contractual restriction on transfer for six months following the applicable grant date, during which the Selling Stockholders may not sell them. Following expiration of that restriction period, a Selling Stockholder may, but is under no obligation to, sell shares covered by this prospectus, and may sell any, all or none of them, in a number of different ways and at varying prices, including sales in the open market, sales in negotiated transactions and sales by a combination of these methods. Registration of the shares does not require any Selling Stockholder to sell and should not be taken as an indication that any Selling Stockholder intends to sell, any shares. We do not know whether, when or in what amount the Selling Stockholders may sell their shares.
Our Common Stock is listed on The Nasdaq Capital Market under the symbol "OSRH." On October 24, 2026, a Nasdaq Hearings Panel determined not to grant the Company's request for continued listing, and trading in our Common Stock on Nasdaq has been suspended. Nasdaq is expected to file a notification on Form 25 with the SEC to delist our Common Stock. Our Common Stock is currently quoted on the OTC Pink market operated by OTC Markets Group Inc. under the symbol "OSRH." There can be no assurance that our Common Stock will be quoted on a higher tier of the OTC market or listed on a national securities exchange. On November 17, 2026, the last reported sale price of our Common Stock was $0.10 per share.
Investing in our securities involves a high degree of risk. Before buying any securities, you should carefully read the discussion of the risks of investing in our securities in the section entitled "Risk Factors" beginning on page 1 of this prospectus.
The Securities and Exchange Commission (the "SEC") may take the view that, under certain circumstances, the Selling Stockholders and any broker-dealers or agents that participate in the distribution of the shares may be deemed to be "underwriters" within the meaning of the Securities Act. Commissions, discounts or concessions received by any such broker-dealer or agent may be deemed to be underwriting commissions under the Securities Act. See the section entitled "Plan of Distribution."
Neither the SEC nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus is November 18, 2026.
TABLE OF CONTENTS
|
Page |
|
|
About this Prospectus |
1 |
|
Our Company |
1 |
|
Risk Factors |
1 |
|
Cautionary Note regarding Forward-Looking Statements |
2 |
|
Use of Proceeds |
3 |
|
Selling Stockholders |
3 |
|
Plan of Distribution |
4 |
|
Legal Matters |
6 |
|
Experts |
6 |
|
Documents Incorporated By Reference |
6 |
|
Where You Can Find More Information |
7 |
You should rely only on the information contained in or incorporated by reference into this prospectus or any prospectus supplement. We have not authorized any person to give any information or to make any representations other than those contained or incorporated by reference in this prospectus, and, if given or made, you must not rely upon such information or representations as having been authorized. This prospectus does not constitute an offer to sell or the solicitation of an offer to buy any securities other than our shares of common stock described in this prospectus or an offer to sell or the solicitation to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should not assume that the information we have included in this prospectus is accurate as of any date other than the date of this prospectus or that any information we have incorporated by reference is accurate as of any date other than the date of the document incorporated by reference regardless of the time of delivery of this prospectus or of any securities registered hereunder
ABOUT THIS PROSPECTUS
This Reoffer Prospectus contains important information you should know before investing, including important information about the Company and the securities being offered. You should carefully read this Reoffer Prospectus, as well as the additional information contained in the documents described under "Where You Can Find More Information" and "Documents Incorporated By Reference" in this Reoffer Prospectus, and in particular the periodic and current reporting documents we file with the Securities and Exchange Commission (the "Commission"). We have not authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. This Reoffer Prospectus is not an offer to sell these securities, and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
You should not assume that the information in this Reoffer Prospectus or any documents we incorporate by reference herein or therein is accurate as of any date other than the date on the front of those documents. Our business, financial condition, results of operations, and prospects may have changed since those dates.
OUR COMPANY
OSR Health, Inc. is a global healthcare holding company incorporated in the State of Delaware. Through our subsidiaries, we focus on the development of innovative therapeutic and healthcare solutions. Our principal subsidiaries include Vaximm AG, a Swiss clinical-stage biopharmaceutical company developing oral cancer vaccines and T-cell immunotherapies, including VXM01, its lead product candidate targeting VEGFR2 for the treatment of glioblastoma and other solid tumors; Darnatein, focused on regenerative biologics for age-related and degenerative diseases; RMC, a medical device distribution and logistics company operating in Korea; and Woori IO, a Korean medical technology company focused on non-invasive glucose monitoring solutions.
Our principal executive offices are located at 10900 NE 4th Street, Suite 2300, Bellevue, WA 98004, and our telephone number is (425) 635-7700.
RISK FACTORS
Investment in any securities offered pursuant to this prospectus and the applicable prospectus supplement involves risks. Before deciding whether to invest in our securities, you should carefully consider the risk factors incorporated by reference to our most recent Annual Report on Form 10-K and any subsequent Current Reports on Form 8-K, and all other information contained or incorporated by reference into this prospectus, as updated by our subsequent filings under the Exchange Act, and the risk factors and other information contained in the applicable prospectus supplement and any applicable free writing prospectus. The occurrence of any of these risks might cause you to lose all or part of your investment in the offered securities. There may be other unknown or unpredictable economic, business, competitive, regulatory or other factors that could have material adverse effects on our future results. Past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. If any of these risks actually occurs, our business, financial condition, results of operations or cash flow could be seriously harmed. This could cause the trading price of our securities to decline, resulting in a loss of all or part of your investment. Please also carefully read the section entitled "Cautionary Note Regarding Forward-Looking Statements" included in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q and any subsequent Current Reports on Form 8-K.
Trading in our Common Stock on The Nasdaq Capital Market has been suspended, our Common Stock is expected to be delisted, and it is currently quoted on the OTC Pink market, which may adversely affect the liquidity and market price of our Common Stock. On October 24, 2026, a Nasdaq Hearings Panel determined not to grant our request for continued listing on The Nasdaq Capital Market, trading in our Common Stock on Nasdaq has been suspended, and our Common Stock is now quoted on the OTC Pink market. Nasdaq is expected to file a notification on Form 25 with the SEC to delist our Common Stock. There can be no assurance that our Common Stock will be quoted on the OTCQB Venture Market or listed on a national securities exchange in the future. Securities quoted on the OTC market are generally subject to greater price volatility, wider bid-ask spreads, lower trading volume, and less analyst coverage than securities listed on a national securities exchange, any of which could make it more difficult for stockholders, including the Selling Stockholders, to sell shares at favorable prices or at all, and could adversely affect our ability to raise capital. In addition, upon the effectiveness of the Form 25 relating to the delisting of our Common Stock, the registration of our Common Stock under Section 12(b) of the Exchange Act will terminate; although we expect to remain subject to the periodic reporting requirements of the Exchange Act, there can be no assurance regarding the continued registration of our Common Stock under Section 12(g) of the Exchange Act.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
1
This prospectus and the documents we have filed with the SEC that are incorporated by reference contain "forward-looking statements" within the meaning of Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical facts contained in this prospectus, including any statements regarding our future results of operations and financial position, business strategy, product candidates, planned preclinical and nonclinical studies and clinical trials, results of preclinical and nonclinical studies, clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.
The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this prospectus may include, for example, statements about:
● our expectations around the performance of the Company, including without limitation, the Company's strategy, future operations, financial performance and position, revenues, projected costs, prospects and plans;
● our ability to obtain quotation of our Common Stock on the OTCQB Venture Market or to list our Common Stock on a national securities exchange;
● our success in retaining or recruiting, or changes required in, our officers, key employees or directors;
● our officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business;
● our ability to successfully and efficiently integrate future expansion plans and opportunities and to grow our business in a cost-effective manner;
● future potential change in control;
● the implementation, market acceptance and success of the Company's business model;
● developments and projections relating to the Company's competitors and industry;
● our expectations regarding the Company's ability to obtain and maintain intellectual property protection and not infringe on the rights of others;
● our public securities' potential liquidity and trading;
● changes in applicable laws or regulations;
● expectations regarding the time during which we will be an "emerging growth company" under the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act");
2
● the outcome of any known and unknown litigation and regulatory proceedings.
The forward-looking statements contained in this prospectus are based on our current expectations and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors listed under the heading "Risk Factors" elsewhere in this prospectus. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and developments in the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in this prospectus. In addition, even if our results or operations, financial condition and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in this prospectus, those results or developments may not be indicative of results or developments in subsequent periods.
USE OF PROCEEDS
The Company will not receive any proceeds from the resale of shares by the Selling Stockholders. All proceeds will be received by the respective Selling Stockholder.
SELLING STOCKHOLDERS
The following table sets forth information regarding beneficial ownership of our common stock as of November 13, 2026, as adjusted to reflect the Shares that may be sold from time to time pursuant to this prospectus, for all Selling Stockholders, consisting of the individuals shown as having shares listed in the column entitled "Shares Being Offered." Each Selling Stockholder has advised the Company that the Shares are held as a long-term investment and that the Selling Stockholder has no present intention to sell any of the Shares, which remain subject to a six-month contractual restriction on transfer following the applicable grant date. The "Shares beneficially owned after offering" column assumes, solely for illustrative purposes and as required by applicable disclosure rules, that each Selling Stockholder sells all of the Shares being offered; it does not reflect any actual or intended sale.
The Shares offered by the Selling Stockholders hereunder consist of an aggregate of 2,507,256 shares of Common Stock issuable pursuant to stock grants granted to certain of our current directors and executive officers under the Company's 2025 Omnibus Incentive Plan.
We have determined beneficial ownership in accordance with the rules of the Securities and Exchange Commission (the "SEC"), and the information is not necessarily indicative of beneficial ownership for any other purpose. Unless otherwise indicated below, to our knowledge, the persons named in the table have sole voting and sole investment power with respect to all shares beneficially owned by them, subject to community property laws where applicable.
In computing the number of shares of Common Stock beneficially owned by a person and the percentage ownership of that person, we deemed outstanding all shares of Common Stock subject to stock grants held by such person that are expected to vest or be issued within 60 days of November 13, 2026. We did not deem such shares outstanding, however, for the purpose of computing the percentage ownership of any other person.
Applicable percentage ownership of our common stock before this offering is based on 35,258,692 shares of Common Stock outstanding as of November 13, 2026.
|
Name and position |
Shares beneficially owned before offering (1) |
Shares being offered (2) |
Shares beneficially owned after offering (assuming all sold) |
|
Kuk Hyoun Hwang Chairman & Chief Executive Officer |
14,242,803 |
1,173,697 |
13,069,106 (35.9%) |
|
Gihyoun Bang Chief Financial Officer |
440,137 |
440,137 |
- |
|
Yeiseok (Jessi) Kim Chief Operating Officer |
318,121 |
293,422 |
24,699 (*) |
|
Reto Fierz Independent Director |
120,000 |
120,000 |
- |
|
Seng Chin Mah Independent Director |
120,000 |
120,000 |
- |
|
Alcide Barberis Independent Director |
120,000 |
120,000 |
- |
|
Joong Myung Cho Independent Director |
120,000 |
120,000 |
- |
|
Hyuk Joo Jee Independent Director |
120,000 |
120,000 |
- |
3
* Less than 1%.
(1) Beneficial ownership is determined in accordance with Rule 13d-3 under the Exchange Act and includes shares issuable upon exercise of options and warrants exercisable within 60 days. Percentage ownership is based on 35,258,692 shares of Common Stock outstanding as of November 13, 2026.
(2) The Award Shares are being issued as registered securities under this Registration Statement and, because the Selling Stockholders may be deemed to be affiliates of the Company, may be deemed to constitute "control securities." To the extent the Selling Stockholders are deemed affiliates, resales by the Selling Stockholders may be subject to the volume, manner-of-sale and current public information requirements of Rule 144 applicable to affiliates, but are not subject to any Rule 144 holding period. The Award Shares are being registered for resale pursuant to this prospectus.
PLAN OF DISTRIBUTION
As of the date of this prospectus, the Selling Stockholders have advised the Company that they have no present intention to sell any of the Shares and intend to hold them as a long-term investment; the following description is provided to satisfy applicable disclosure requirements should a Selling Stockholder determine to sell in the future. We are registering the Shares covered by this prospectus to permit the Selling Stockholders to conduct public secondary trading of these Shares from time to time after the date of this prospectus. We will not receive any of the proceeds of the sale of the Shares offered by this prospectus. The aggregate proceeds to the Selling Stockholders from the sale of the Shares will be the purchase price of the Shares less any discounts and commissions. We will not pay any brokers' or underwriters' discounts and commissions in connection with the registration and sale of the Shares covered by this prospectus. The Selling Stockholders reserve the right to accept and, together with their respective agents, to reject, any proposed purchases of Shares to be made directly or through agents.
The Shares offered by this prospectus may be sold from time to time to purchasers:
● directly by the Selling Stockholders, or
4
● through underwriters, broker-dealers or agents, who may receive compensation in the form of discounts, commissions or agent's commissions from the Selling Stockholders or the purchasers of the Shares.
Any underwriters, broker-dealers or agents who participate in the sale or distribution of the Shares may be deemed to be "underwriters" within the meaning of the Securities Act. As a result, any discounts, commissions or concessions received by any such broker-dealers or agents who are deemed to be underwriters will be deemed to be underwriting discounts and commissions under the Securities Act. Underwriters are subject to the prospectus delivery requirements of the Securities Act and may be subject to certain statutory liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended (the "Exchange Act"). We will make copies of this prospectus available to the Selling Stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. To our knowledge, there are currently no plans, arrangements or understandings between the Selling Stockholders and any underwriter, broker-dealer or agent regarding the sale of the Shares by the Selling Stockholders.
The Shares may be sold in one or more transactions at:
● fixed prices;
● prevailing market prices at the time of sale;
● prices related to such prevailing market prices;
● varying prices determined at the time of sale; or
● negotiated prices.
These sales may be effected in one or more transactions:
● on any national securities exchange or quotation service on which the Shares may be listed or quoted at the time of sale, if any;
● in the over-the-counter market;
● in transactions otherwise than on such exchanges or services or in the over-the-counter market;
● any other method permitted by applicable law; or
● through any combination of the foregoing.
These transactions may include block transactions or crosses. Crosses are transactions in which the same broker acts as an agent on both sides of the trade.
At the time a particular offering of the Shares is made, a prospectus supplement, if required, will be distributed, which will set forth the name of the Selling Stockholders, the aggregate amount of Shares being offered, and the terms of the offering, including, to the extent required, (1) the name or names of any underwriters, broker-dealers or agents, (2) any discounts, commissions and other terms constituting compensation from the Selling Stockholders and (3) any discounts, commissions or concessions allowed or reallowed to be paid to broker-dealers.
The Selling Stockholders will act independently of us in making decisions with respect to the timing, manner and size of each resale or other transfer following expiration of the applicable contractual restriction period. The shares issuable pursuant to the awards are subject to a contractual restriction on transfer and sale for a period of six months following the applicable grant date, and, accordingly, the Selling Stockholders may not offer, sell or otherwise transfer the shares prior to the expiration of such restriction period, notwithstanding the effectiveness of the registration statement of which this prospectus forms a part. There can be no assurance that the Selling Stockholders will sell any or all of the Shares under this prospectus. Further, we cannot assure you that the Selling Stockholders will not transfer, distribute, devise or gift the Shares by other means not described in this prospectus. In addition, any Shares covered by this prospectus that qualify for sale under Rule 144 of the Securities Act may be sold under Rule 144 rather than under this prospectus. Because the Company does not currently satisfy the registrant requirements for primary use of Form S-3, the number of shares that each Selling Stockholder, together with any person with whom he or she is acting in concert, may reoffer or resell pursuant to this reoffer prospectus during any three-month period is limited to the amount specified in Rule 144(e) under the Securities Act, determined in accordance with General Instruction C.3 to Form S-8. The Shares may be sold in some states only through registered or licensed brokers or dealers. In addition, in some states the Shares may not be sold unless they have been registered or qualified for sale or an exemption from registration or qualification is available and complied with.
5
Certain Selling Stockholders may have enrolled some or all of their shares of Common Stock in the Company's Shareholder Loyalty CVR Program. To the extent any Shares covered by this prospectus are subject to that program, the applicable terms may affect a Selling Stockholder's decision whether and when to resell such Shares. Additional information regarding the program is contained in the Company's filings with the SEC that are incorporated by reference into this prospectus.
The Selling Stockholders and any other person participating in the sale of the Shares will be subject to the Exchange Act. The Exchange Act rules include, without limitation, Regulation M, which may limit the timing of purchases and sales of any of the Shares by the Selling Stockholders and any other person. In addition, Regulation M may restrict the ability of any person engaged in the distribution of the Shares to engage in market-making activities with respect to the particular Shares being distributed. This may affect the marketability of the Shares and the ability of any person or entity to engage in market-making activities with respect to the Shares.
The Selling Stockholders may indemnify any broker or underwriter that participates in transactions involving the sale of the Shares against certain liabilities, including liabilities arising under the Securities Act.
LEGAL MATTERS
The validity of the shares of Common Stock registered hereby will be passed upon by Jun Chul Whang, Chief Legal Officer of the Company.
EXPERTS
The consolidated financial statements of OSR Health, Inc. as of and for the year ended December 31, 2025, incorporated by reference in this prospectus, have been audited by Shinhan Accounting Corporation, an independent registered public accounting firm, as stated in their report incorporated by reference herein, which report includes an explanatory paragraph describing conditions that raise substantial doubt about the Company's ability to continue as a going concern. Such financial statements are incorporated herein by reference in reliance upon the report of such firm given upon their authority as experts in accounting and auditing.
DOCUMENTS INCORPORATED BY REFERENCE
The SEC's rules allow us to "incorporate by reference" information into this prospectus, which means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is deemed to be part of this prospectus, and subsequent information that we file with the SEC will automatically update and supersede that information. Any statement contained in this prospectus or a previously filed document incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or a subsequently filed document incorporated by reference modifies or replaces that statement.
This prospectus and any accompanying prospectus supplement incorporate by reference the documents set forth below that have previously been filed with the SEC:
6
• our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on March 31, 2026;
• our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026, June 30, 2026 and September 30, 2026, filed with the SEC on May 13, 2026, August 14, 2026 and November 13, 2026, respectively;
• our Current Reports on Form 8-K filed with the SEC on January 14, 2026, January 27, 2026, March 10, 2026, March 16, 2026, April 2, 2026, April 9, 2026, April 22, 2026, April 30, 2026, June 2, 2026, June 11, 2026, June 17, 2026, July 31, 2026, August 7, 2026, August 10, 2026, August 19, 2026, August 25, 2026, August 28, 2026, October 2, 2026, October 16, 2026, October 28, 2026 and November 13, 2026, and our Current Reports on Form 8-K/A filed with the SEC on April 3, 2026 and May 6, 2026 (in each case other than information furnished under Item 2.02 or Item 7.01 and related exhibits); and
• the description of our Common Stock contained in our registration statement on Form 8-A (File No. 001-41390) filed with the SEC on May 11, 2022, as updated by the description under the heading "Description of Securities" beginning on page 328 of the proxy statement/prospectus filed with the SEC on January 31, 2025 in connection with our Registration Statement on Form S-4 (File No. 333-280590), as incorporated by reference into our Current Report on Form 8-K filed with the SEC on February 21, 2025, and any amendment or report filed for the purpose of updating such description.
All reports and other documents we subsequently file pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, which we refer to as the "Exchange Act" in this prospectus, prior to the termination of this offering, including all such documents we may file with the SEC after the date of the initial registration statement and prior to the effectiveness of the registration statement, but excluding any information furnished to, rather than filed with, the SEC, will also be incorporated by reference into this prospectus and deemed to be part of this prospectus from the date of the filing of such reports and documents.
You may request a free copy of any of the documents incorporated by reference in this prospectus by writing or telephoning us at the following address:
OSR Health, Inc.
10900 NE 4th Street, Suite 2300
Bellevue, WA 98004
(425) 635-7700
Exhibits to the filings will not be sent, however, unless those exhibits have specifically been incorporated by reference in this prospectus or any accompanying prospectus supplement.
WHERE YOU CAN FIND MORE INFORMATION
We file reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy and information statements and other information about issuers, such as us, who file electronically with the SEC. The address of that website is http://www.sec.gov.
Our website address is https://www.osr-health.com. The information on our website, however, is not, and should not be deemed to be, a part of this prospectus.
This prospectus and any prospectus supplement are part of a registration statement that we filed with the SEC and do not contain all of the information in the registration statement. The full registration statement may be obtained from the SEC or us, as provided below. Documents establishing the terms of the offered securities are or may be filed as exhibits to the registration statement or documents incorporated by reference in the registration statement. Statements in this prospectus or any prospectus supplement about these documents are summaries and each statement is qualified in all respects by reference to the document to which it refers. You should refer to the actual documents for a more complete description of the relevant matters. You may inspect a copy of the registration statement through the SEC's website, as provided above.
7
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The SEC's rules allow us to "incorporate by reference" information into this Registration Statement, which means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is deemed to be part of this Registration Statement, and subsequent information that we file with the SEC will automatically update and supersede that information. Any statement contained in this Registration Statement or a previously filed document incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or a subsequently filed document incorporated by reference modifies or replaces that statement.
The following documents previously filed by the Registrant with the SEC are incorporated by reference into this Registration Statement:
• our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on March 31, 2026;
• our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026, June 30, 2026 and September 30, 2026, filed with the SEC on May 13, 2026, August 14, 2026 and November 13, 2026, respectively;
• our Current Reports on Form 8-K filed with the SEC on January 14, 2026, January 27, 2026, March 10, 2026, March 16, 2026, April 2, 2026, April 9, 2026, April 22, 2026, April 30, 2026, June 2, 2026, June 11, 2026, June 17, 2026, July 31, 2026, August 7, 2026, August 10, 2026, August 19, 2026, August 25, 2026, August 28, 2026, October 2, 2026, October 16, 2026, October 28, 2026 and November 13, 2026, and our Current Reports on Form 8-K/A filed with the SEC on April 3, 2026 and May 6, 2026 (in each case other than information furnished under Item 2.02 or Item 7.01 and related exhibits); and
• the description of our Common Stock contained in our registration statement on Form 8-A (File No. 001-41390) filed with the SEC on May 11, 2022, as updated by the description under the heading "Description of Securities" beginning on page 328 of the proxy statement/prospectus filed with the SEC on January 31, 2025 in connection with our Registration Statement on Form S-4 (File No. 333-280590), as incorporated by reference into our Current Report on Form 8-K filed with the SEC on February 21, 2025, and any amendment or report filed for the purpose of updating such description.
All reports and other documents we subsequently file pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, which we refer to as the "Exchange Act" in this prospectus, after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, including all such documents we may file with the SEC after the date of the initial registration statement and prior to the effectiveness of the registration statement, but excluding any information furnished to, rather than filed with, the SEC, will also be incorporated by reference into this Registration Statement and deemed to be part of this Registration Statement from the date of the filing of such reports and documents.
You may request a free copy of any of the documents incorporated by reference in this prospectus by writing or telephoning us at the following address:
OSR Health, Inc.
10900 NE 4th Street, Suite 2300
Bellevue, WA 98004
II-1
(425) 635-7700
Exhibits to the filings will not be sent, however, unless those exhibits have specifically been incorporated by reference in this prospectus or any accompanying prospectus supplement.
Item 4. Description of Securities
Not applicable.
Item 5. Interests of Named Experts and Counsel
The validity of the shares of Common Stock offered hereby has been passed upon for the Company by Jun Chul Whang, the Company's Chief Legal Officer. Mr. Whang is an officer, director and employee of the Company. He was not engaged on a contingent basis to render such opinion, does not beneficially own any shares of the Company's Common Stock, and has no other substantial interest, direct or indirect, in the Company.
Item 6. Indemnification of Directors and Officers.
As permitted by Section 102 of the Delaware General Corporation Law, the Registrant adopted provisions in its amended and restated certificate of incorporation and amended and restated bylaws, which became effective immediately prior to the completion of the Registrant's business combination, that limit or eliminate the personal liability of its directors and officers for a breach of their fiduciary duty of care as a director or officer. The duty of care generally requires that, when acting on behalf of the corporation, directors and officers exercise an informed business judgment based on all material information reasonably available to them. Consequently, a director or officer will not be personally liable to the Registrant or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, except for liability for:
● any breach of the director's or officer's duty of loyalty to the Registrant or its stockholders;
● any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
● any act related to unlawful stock repurchases, redemptions or other distributions or payment of dividends; or
● any transaction from which the director or officer derived an improper personal benefit.
These limitations of liability do not affect the availability of equitable remedies such as injunctive relief or rescission. The Registrant's amended and restated certificate of incorporation and amended and restated bylaws also authorize the Registrant to indemnify its officers, directors and other agents to the fullest extent permitted under Delaware law.
As permitted by Section 145 of the Delaware General Corporation Law, the Registrant's amended and restated bylaws provide that:
● the Registrant may indemnify its directors, officers and employees to the fullest extent permitted by the Delaware General Corporation Law, as amended, subject to limited exceptions;
● the Registrant may advance expenses to its directors, officers and employees in connection with a legal proceeding to the fullest extent permitted by applicable law, subject to limited exceptions; and
● the rights provided in its amended and restated bylaws are not exclusive.
The Registrant's amended and restated certificate of incorporation and its amended and restated bylaws provide for the indemnification provisions described above and elsewhere herein. The Registrant has entered into, and intends to continue to enter into, separate indemnification agreements with its directors and officers that may be broader than the specific indemnification provisions contained in the Delaware General Corporation Law. These indemnification agreements generally require the Registrant, among other things, to indemnify its officers and directors against certain liabilities that may arise by reason of their status or service as directors or officers, if the officer or director acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Registrant and, in the case of a criminal proceeding, had no reasonable cause to believe that his or her conduct was unlawful. These indemnification agreements also generally require the Registrant to advance any expenses incurred by the directors or officers as a result of any proceeding against them as to which they could be indemnified. These indemnification provisions and the indemnification agreements may be sufficiently broad to permit indemnification of the Registrant's officers and directors for liabilities, including reimbursement of expenses incurred, arising under the Securities Act.
II-2
The Registrant has entered into indemnification agreements with its directors and officers pursuant to which the Registrant has agreed to indemnify such persons, subject to the terms of the applicable agreements and applicable law, against certain liabilities, losses, claims, damages and expenses that may arise by reason of their service as directors or officers of the Registrant. These indemnification agreements provide rights to indemnification that are in addition to the rights provided under the Registrant's amended and restated certificate of incorporation, amended and restated bylaws and the Delaware General Corporation Law. These indemnification provisions and agreements may be sufficiently broad to permit indemnification of the Registrant's directors and officers for liabilities arising under the Securities Act.See also the Undertakings set forth in the response to Item 9 herein.
Item 7. Exemption from Registration Claimed
Not applicable. All shares of Common Stock covered by this Registration Statement, including the shares covered by the reoffer prospectus, are being issued for the first time as registered securities under this Registration Statement. No such shares were issued prior to the filing of this Registration Statement in reliance on any exemption from registration under the Securities Act, and accordingly no claim of exemption from registration is made.
Item 8. Exhibits
The following exhibits are filed herewith or are incorporated herein by reference.
|
Exhibit |
Description |
|
4.1 |
OSR Health, Inc. 2025 Omnibus Incentive Plan, as updated to reflect the change of the Registrant's name* (originally filed as Annex H to the Registrant's Registration Statement on Form S-4 (File No. 333-280590), filed with the SEC on January 29, 2025, and incorporated by reference as Exhibit 10.27 thereto) |
|
4.2 |
Form of Amended and Restated Stock Award Agreement (Employee Unpaid Salary Make-Whole Award)* |
|
4.3 |
Form of Amended and Restated Stock Award Agreement (Independent Director Equity Award)* |
|
5.1 |
Opinion of Jun Chul Whang, Chief Legal Officer of the Company, as to the validity of the shares of Common Stock being registered* |
|
23.1 |
Consent of Shinhan Accounting Corporation, independent registered public accounting firm* |
|
23.2 |
Consent of Jun Chul Whang (included in Exhibit 5.1) |
|
24.1 |
Power of Attorney (included on the signature page of this Registration Statement) |
|
107 |
Filing Fee Table* |
* Filed herewith.
Item 9. Undertakings
(a) The registrant hereby undertakes:
II-3
(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement; and
(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;
provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if this Registration Statement is on Form S-8 and the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the SEC by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.
(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
(b) The registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
II-4
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Bellevue, State of Washington, on November 18, 2026.
OSR HEALTH, INC.
By: /s/ Kuk Hyoun Hwang
Kuk Hyoun Hwang
Chief Executive Officer
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Jun Chul Whang and Tim Smith, acting singly, as true and lawful attorneys-in-fact and agents, with full powers of substitution and resubstitution, for them and in their name, place and stead, in any and all capacities, to sign any and all amendments to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, and generally to do all such things in their names and behalf in their capacities as officers and directors to enable the Company to comply with the provisions of the Securities Act of 1933 and all requirements of the SEC, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or their substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.
|
Name |
Position |
Date |
|
/s/ Kuk Hyoun Hwang Kuk Hyoun Hwang |
Chief Executive Officer and Director (Principal Executive Officer) |
November 18, 2026 |
|
/s/ Jun Chul Whang Jun Chul Whang |
Chief Legal Officer and Director |
November 18, 2026 |
|
/s/ Gihyoun Bang Gihyoun Bang |
Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |
November 18, 2026 |
|
/s/ Alcide Barberis Alcide Barberis |
Director |
November 18, 2026 |
|
/s/ Seng Chin Mah Seng Chin Mah |
Director |
November 18, 2026 |
|
/s/ Hyuk Joo Jee Hyuk Joo Jee |
Director |
November 18, 2026 |
|
/s/ Joong Myung Cho Joong Myung Cho |
Director |
November 18, 2026 |
|
/s/ Reto Fierz Reto Fierz |
Director |
November 18, 2026 |
II-5